> ## Content Index
> Fetch the complete content index at: https://www.metatalks.ai/llms.txt
> Use this file to discover other available public pages before exploring further.

# Why MedTech M&A Is Accelerating Again in 2026
- URL: https://www.metatalks.ai/why-medtech-m-a-is-accelerating-again-in-2026/
- Published: 2026-10-22T14:14:40.000Z
- Updated: 2026-10-22T14:14:40.000Z
- Author: Mark Tiangov
- Tags: MedTechMA, AIinHealthcare, MedicalDevices

Dealmakers in medical technology are heading into the final quarter of 2026 with growing confidence and a clear sense that they need to act. After two years of macroeconomic instability and regulatory uncertainty, MedTech M&A is picking up again, and this time strategic goals are driving it.

After the latest run of external shocks, executives have learned to see acquisitions as more than a tool for straightforward growth. They now treat deals as a way to control costs and protect profitability. Strong financial positions and a growing need to rework product portfolios are pushing companies toward deals that reduce risk.

The cost of capital fell after the US Federal Reserve cut its key rate three times in the second half of 2025, although the Fed raised it again in September 2026\. Meanwhile, the economic consequences of global disruptions have proved less severe than expected, and AI's potential in healthcare is still far from fully realized.

The market opened up room to act, helped by lower company valuations and the recognition that companies need to get more out of AI. In the first nine months of 2026, MedTech M&A reached $81 billion, compared with $37.6 billion for the same period of 2025, according to BioWorld.

What is happening in MedTech is hard to write off as another turn of the market cycle. Behind the renewed interest in M&A are several structural shifts that are changing the logic of dealmaking itself.

## Buyers Pay for Proven AI

Buyers check a target's AI closely, but they pay only for results. AI has not yet become a separate valuation multiplier, according to an August review by Middle Branch Partners, and deals made mainly to buy AI capability were re-rated lower in 2026\. The premium goes to AI that already works in clinical practice.

In practice, that means solutions that fit into clinical workflows, reduce physicians' workload, or measurably improve decision accuracy. In medical imaging, for example, triage software flags a suspected brain hemorrhage on a CT scan and moves the study to the top of the worklist before a radiologist opens it.

During due diligence, buyers assess AI assets the way they assess investment risk. They ask what exactly improves and by how much, whether clinics actually use the product, and how much it costs to support.

Developing these capabilities in-house is slow and expensive, so buyers increasingly acquire companies they have already tested as partners:

- Roche agreed to acquire digital pathology company PathAI for $750 million upfront and up to $300 million in milestone payments. The two companies have worked together on AI algorithms for companion diagnostics since 2024.
- Medtronic completed its $585 million acquisition of CathWorks, which it had held an option to buy since 2022\. The FFRangio system calculates fractional flow reserve, a measure of ischemia, from a routine coronary angiogram without a pressure wire, directly in the cath lab.

For a company that postpones serious investment in AI, every quarter works in favor of its competitors. They collect proprietary data, refine their models, and build relationships with the buyers who will later decide what the slower company is worth.

## GLP-1 Drugs Push Device Makers to Hedge

Fast uptake of GLP-1 weight-loss drugs is already changing demand for medical devices. The drugs can reduce device use in bariatric surgery, type 2 diabetes care, and sleep apnea treatment. According to JAMA Surgery, the share of eligible US adults undergoing bariatric surgery fell 46% between late 2022 and the third quarter of 2025\. Over the same period, GLP-1 prescriptions rose, and more patients now try the drugs before an invasive procedure.

MedTech companies are responding in two directions. Some buy assets that depend less on the procedure volumes GLP-1 drugs are eroding. Others move into treating severe complications of obesity and diabetes, such as venous thromboembolism, severe heart failure, and complex cardiovascular disease, where patients still need device-based interventions however widely the drugs are used.

Deal activity this year has been heaviest in the cardiovascular and neurovascular segments, where treatment still depends on medical devices:

- Boston Scientific announced the acquisition of Penumbra at an enterprise value of about $14.5 billion. Penumbra develops mechanical thrombectomy systems for stroke, pulmonary embolism, and peripheral thrombosis. This is the largest MedTech deal of 2026 so far. The FTC is reviewing it, and Boston Scientific expects to close by the end of the year.
- Boston Scientific also invested $1.5 billion for a stake of about 34% in MiRus, which develops a transcatheter valve for aortic stenosis. Once MiRus reaches certain clinical and regulatory milestones, Boston Scientific can buy its TAVR business for another $3 billion.
- Medtronic completed its acquisition of Scientia Vascular, a maker of neurovascular guidewires and catheters, valued at $550 million.
- Stryker completed its acquisition of Amplitude Vascular Systems, which develops intravascular lithotripsy for calcified lesions in peripheral arteries, for about $435 million upfront and up to $400 million in milestone payments.
- Haemonetics completed its acquisition of Vivasure for €100 million upfront and up to €85 million tied to sales growth and other milestones, adding a closure device for large-bore vascular access in structural heart procedures.

## Compliance Costs Force Consolidation

Approval based on safety and efficacy data is now only the first step. In the EU, the Medical Device Regulation requires post-market surveillance for as long as a device is sold, and devices certified under the old directives must move to MDR certificates by the end of 2027 or 2028, depending on their risk class. In the US, the FDA's new quality management rule took effect in February 2026\. Compliance has turned from a one-time task before launch into a recurring expense.

Not every company can carry this cost, and that gap produces deals. Large players buy smaller competitors for their technologies and for their regulatory approvals, which buyers now price as separate assets. Companies without the capital to pass every review end up selling to those that have it.

A similar calculation brings US corporate venture funds to Europe. According to Nelson Advisors, they seek early access to European robotics and AI developers before these companies reach US-level valuations. The gap is wide: PitchBook puts the median pre-money valuation of European AI startups at €8.3 million, against €64.2 million in the US.

## Care Moves Out of the Hospital

In 2026, care continues to move from traditional inpatient facilities to ambulatory centers and clinics, which cost less and handle more patients, and to patients' homes. Medicare is pushing in the same direction: CMS has begun a three-year phase-out of its inpatient-only list, starting with 285 mostly musculoskeletal procedures in 2026, and added 289 procedures to the list it covers in ambulatory surgery centers.

MedTech buyers are following these procedures. They increasingly target technologies that let clinicians perform high-volume orthopedic and cardiology procedures safely and efficiently outside the hospital.

Key deals reflecting this shift:

- Danaher completed its acquisition of Masimo at an enterprise value of about $9.9 billion, the year's largest monitoring deal. Masimo works mainly in acute care, so the deal fits this shift through a smaller line: devices that let clinicians monitor patients remotely at home.
- Merit Medical completed its acquisition of View Point Medical for about $140 million, adding OneMark tissue markers that help clinicians localize breast lesions during biopsy, usually an outpatient procedure.
- American Industrial Partners completed its acquisition of Avanos in a transaction valued at about $1.27 billion. Avanos sells pain management and enteral feeding products that patients use in outpatient settings and at home after surgery or acute illness.

## Buying the Capabilities of a New Healthcare Model

Healthcare is moving from paying for the volume of services to paying for patient outcomes, and from treating illness to preventing it. Payers and providers compare the model they want with the one they have and fund what helps close the gap.

For MedTech companies, M&A remains the fastest way to gain capabilities in preventive medicine, AI, and care delivered wherever the patient is. Developing them in-house takes longer and costs more, so buyers pay for companies that already have them.

Two things will show whether this pace lasts into 2027: how the Fed's September rate increase affects deal financing, and whether the FTC clears Boston Scientific's $14.5 billion purchase of Penumbra, the largest deal of the year.